Open AccessThe values of the modified
bronchodilation test glycopyrronium to identify the reversibility of bronchial obstruction in patients with chronic obstructive pulmonary disease.
Author(s) -
N.V. Sharova,
Д. В. Черкашин,
C. L. Grishaev,
Г. Г. Кутелев,
А. В. Чумаков
Publication year - 2018
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2018-96-2-158-163
Subject(s) - bronchodilatation , medicine , bronchodilation , glycopyrrolate , bronchodilator , copd , bronchodilator agents , salbutamol , spirometry , anticholinergic , tracheobronchomalacia , anesthesia , fluticasone , ipratropium bromide , anticholinergic agents , airway obstruction , asthma , airway , atropine
Proposed modification of a bronchodilation test with sequential use of rapidly acting bronchodilators: anticholinergic actions glycopyrronium bromide 50 μg and β2-agonist - salbutamol 400 mcg in patients with stable COPD. Modified bronchodilatation test (MBT), was performed in 48 patients with stable COPD, revealed signs of reversible bronchial obstruction more often than the standard BDT (in 76% of cases, against 25% in primary and 36% in the control groups, respectively). The magnitude of the bronchodilator effect glycopyrrolate, defined on spirometry, comparable to that in sbdt in patients with COPD. The degree of increase in FEV1, FVC, POS patients after MDT was significantly higher than that in the standard theatre (sbdt), which confirms the synergistic effect of double bronchodilatation. Holding mbdt is recommended for detection of reversibility of bronchial obstruction in patients with COPD.